All stock lists
IperionX Limited (NASDAQ:IPX)
US · Delayed Price · Currency is USD
Basic Materials · Other Precious Metals
$9.96-$1.38 (-12.17%)
Market cap
$334M
Insider Score
Health Score
Analyst consensus
Listed since
Jun 21, 2022
Website
Insider Score
––Not scored
IPX Insider Score
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
Financial Health Score
Fair
From IPX’s reported statements · Q2 2026 (trailing 12 months) · 4 of 5 pillars
Profitability—
No revenue reported, so there is no margin to score.
- Revenue
- $0
- Net income
- -$102.3M
- Net margin
- —
Leverage20 / 20
Little or no net debt.
- Total debt
- $4.2M
- Cash
- $35.2M
- Debt / equity
- 0.05
Liquidity20 / 20
Comfortably covers what is due within a year.
- Current assets
- $44.0M
- Current liabilities
- $13.6M
- Current ratio
- 3.24
Cash generation3 / 20
Consumes cash and must keep raising it.
- Operating cash flow
- -$60.0M
- Free cash flow
- -$91.1M
Dilution & runway1 / 20
Burning cash with under a year of runway — expect a raise.
- Shares outstanding
- 3.4M
- Share growth (1y)
- -85.0%
- Cash runway
- 7 months
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
IPX Income Statement
| Fiscal Period | Q2 2026 | Q4 2025 | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Dec 31, 2025 | Jun 30, 2025 | Dec 30, 2024 | Jun 30, 2024 | Dec 30, 2023 |
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue Growth (YoY) | — | — | — | — | — | — |
| Cost of Revenue | $2.41 M | $1.95 M | $728.18 K | $1.55 M | $353.28 K | $294.68 K |
| Gross Profit | -$2.41 M | -$1.95 M | -$728.18 K | -$1.55 M | -$353.28 K | -$294.68 K |
| SG&A Expense | $16.34 M | $23.92 M | $26.51 M | $13.73 K | $3.77 K | $3.18 K |
| R&D Expense | $14.46 M | $10.80 M | $12.74 M | $6.81 K | $2.47 K | $1.88 K |
| Operating Expenses | $30.80 M | $34.72 M | $39.25 M | $20.54 K | $12.14 M | $5.06 K |
| Operating Income | -$33.21 M | -$36.67 M | -$18.74 M | -$20.46 M | -$6.25 K | -$10.20 M |
| Pretax Income | -$32.11 M | -$34.83 M | -$19.12 M | -$16.24 K | -$5.67 K | -$10.58 M |
| Tax Provision | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$32.11 M | -$34.83 M | -$35.33 M | -$16.24 K | -$5.67 K | -$5.25 K |
| EPS (Basic) | -$9.50 | -$10.40 | -$0.00 | -$0.06 | -$0.05 | -$5.00 |
| EPS (Diluted) | -$9.50 | -$10.40 | -$0.00 | -$0.06 | -$0.05 | -$5.00 |
| Shares Outstanding | 3.39 M | 3.36 M | 29.46 M | 27.06 M | 22.58 M | 20.99 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.
